Back to today’s briefing

Story perspectives

Sodium Benzoate Shows Promise in Mild Alzheimer's Trial

9/23/2025

50 4

Summary

Story summary

Sodium benzoate may lower disease-related proteins in mild Alzheimer's disease and improve cognition.
24-week trial with 149 participants aged 50–100 tested 500/750/1000 mg doses vs placebo.
Higher baseline amyloid-beta 1–42 levels correlated with greater cognitive benefit from sodium benzoate.
Limitations include moderate sample size and short duration; future work should explore higher doses and blood-brain amyloid-beta links for safer therapies.

1 of 1

Story summary

Sodium benzoate may lower disease-related proteins in mild Alzheimer's disease and improve cognition.
24-week trial with 149 participants aged 50–100 tested 500/750/1000 mg doses vs placebo.
Higher baseline amyloid-beta 1–42 levels correlated with greater cognitive benefit from sodium benzoate.
Limitations include moderate sample size and short duration; future work should explore higher doses and blood-brain amyloid-beta links for safer therapies.